Is Palantir Stock Still Overvalued?

Palantir is still growing rapidly, with analysts forecasting 74% revenue growth next quarter and Q4 net income margins reaching a record 43%, but the stock remains expensive at 231x trailing earnings and 111x forward earnings. The article argues the current valuation already prices in years of strong growth and concludes the shares are still overvalued despite the pullback of roughly 30% from the all-time high.

Analysis

PLTR’s issue is no longer product-market fit; it is duration risk. When a software name is priced on near-perfect multi-year compounding, the equity becomes extremely sensitive to any deceleration in growth rates or margin normalization, even if the absolute business remains excellent. That creates a classic “good company, bad stock” setup where the first derivative can stay strong while the second derivative becomes the entire trade.

The more interesting second-order effect is competitive capital allocation. PLTR’s premium multiple implicitly subsidizes aggressive hiring, customer acquisition, and product expansion, while giving competitors a cheaper relative currency to fund AI adjacent initiatives. That can pull enterprise AI budget share toward larger platform vendors and away from point solutions if buyers decide they want stack consolidation rather than best-in-class niche software.

Consensus may be underestimating how quickly sentiment can swing once high-expectation software loses narrative momentum. With a valuation that already discounts several years of hypergrowth, even a modest miss on next-quarter ARR or billings could compress multiple sharply over weeks, not years. The asymmetry is poor for longs here: upside requires sustained execution plus continued multiple support, while downside can come from either slower growth or a market-wide rotation out of long-duration AI winners.

The contrarian long case is not that PLTR is cheap, but that “expensive” names with visible AI monetization can remain expensive longer than valuation models suggest if institutional investors are forced to own the scarce winners. Still, the cleaner setup is to fade exuberance via structure rather than outright conviction shorting, because fundamental momentum remains strong and borrow/short squeeze risk is real.

Key Decisions for Investors

• Initiate a tactical short PLTR or buy 1-2 month put spreads into any post-earnings strength; target a 15-25% drawdown if growth reaccelerates less than the market is discounting. Use defined risk because squeeze risk remains elevated.
• Pair trade: long NVDA / short PLTR for 6-12 weeks to express AI capex monetization over application-layer valuation excess. NVDA has more direct revenue linkage to AI budgets, while PLTR carries much richer multiple risk.
• If already long PLTR, hedge by selling upside calls against spot into rallies; the risk/reward skews toward capping gains in exchange for premium while the multiple is still stretched.
• Avoid adding fresh long exposure until there is a material reset in valuation or a clear multi-quarter billings acceleration beyond current expectations; the stock needs time, not just momentum, to justify ownership.
• Watch for any slowdown in commercial growth or net retention over the next 1-2 quarters as the key reversal trigger; that would likely catalyze a fast multiple compression trade.